Author Interviews, Endocrinology, Weight Research / 16.01.2015

Caroline M. Apovian, MD Chair of the Endocrine Society task force that developed “Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline” Boston University School of Medicine Boston Medical CenterMedicalResearch.com interview with: Caroline M. Apovian, MD Chair of the Endocrine Society task force that developed “Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline” Boston University School of Medicine Boston Medical Center MedicalResearch: What is the background for this report? Dr. Apovian: The Food and Drug Administration has approved four new anti-obesity drugs – lorcaserin, phentermine/topiramate, naltrexone/bupropion and liraglutide – in the past two years. To help clinicians navigate this changing landscape, the Endocrine Society developed its Clinical Practice Guideline to provide strategies for prescribing drugs to manage obesity and promote weight loss. MedicalResearch: What are the main findings? Dr. Apovian: In the Clinical Practice Guideline, the Endocrine Society recommends that diet, exercise and behavioral modifications be part of all obesity management approaches. Other tools such as weight loss medications and bariatric surgery can be combined with behavioral changes to reduce food intake and increase physical activity, in appropriate patients. Patients who have been unable to successfully lose weight and maintain a goal weight may be candidates for prescription medication if they meet the criteria on the drug’s label as well as BMI criteria (BMI greater than or equal to 30 or greater than or equal to 27 with at least one comorbidity). Other recommendations from the CPG include:
  • If a patient responds well to a weight loss medication and loses 5 percent or more of their body weight after three months, the medication can be continued. If the medication is ineffective or the patient experiences side effects, the prescription should be stopped and an alternative medication or approach considered.
  • Since some diabetes medications are associated with weight gain, people with diabetes who are obese or overweight should be given medications that promote weight loss or have no effect on weight as first- and second-line treatments. Doctors should discuss medications’ potential effects on weight with patients.
  • Certain types of medication – angiotensin converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers – should be used as a first-line treatment for high blood pressure in obese people. These are effective blood pressure treatments that are less likely to contribute to weight gain than an alternative medication, beta-adrenergic blockers.
  • When patients need medications that can have an impact on weight such as antidepressants, antipsychotic drugs and medications for treating epilepsy, they should be fully informed and provided with estimates of each option’s anticipated effect on weight. Doctors and patients should engage in a shared-decision making process to evaluate the options.
  • In patients with uncontrolled high blood pressure or a history of heart disease, the medications phentermine and diethylpropion should not be used.
(more…)
Author Interviews, Endocrinology, JCEM, Menopause, UCLA / 20.12.2014

Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at University of California, Los Angeles UCLA Medicine/GIM Los Angeles, CA 90024MedicalResearch.com Interview with: Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine UCLA Medicine/GIM Los Angeles, California 90024 Medical Research: What is the background for this study? What are the main findings? Dr. Crandall: In a large group of postmenopausal women aged 50-79, we found that women who reporting having hot flashes at baseline had increased risk of hip fracture during the subsequent 8 years of observation, nearly double the risk compared with women who did not have hot flashes at baseline. (more…)
Endocrinology, Kidney Disease, Vitamin D / 19.11.2014

Stuart M. Sprague, DO, FACP, FASN, FNKF Chairperson, Division of Nephrology and Hypertension NorthShore University HealthSystem Evanston, Illinois 60201MedicalResearch.com Interview with:with Stuart M. Sprague, DO, FACP, FASN, FNKF Chairperson, Division of Nephrology and Hypertension NorthShore University HealthSystem Evanston, Illinois 60201 Medical Research: Congratulations, Dr. Sprague, on your presentation of another successful phase 3 clinical trial program at the recently concluded Annual Meeting of the American Society of Nephrology. Your presentation unveiled a new vitamin D repletion therapy that effectively controls secondary hyperparathyroidism in chronic kidney disease. Can you give us a little background for the presented studies? Dr. Sprague: Thanks! Vitamin D insufficiency is a big problem in chronic kidney decease (or CKD): it afflicts more than 20 million adults in the United States who have stages 1 through 4 CKD. Its prevalence increases with CKD severity and it drives secondary hyperparathyroidism. The studies which I presented evaluated a novel therapy to treat secondary hyperparathyroidism (SHPT) arising from vitamin D insufficiency in patients diagnosed with stage 3 or 4 CKD. This new therapy is a modified-release formulation of calcifediol. Medical Research: Can you tell us more about vitamin D insufficiency? Dr. Sprague: Vitamin D insufficiency is a condition in which the body has low vitamin D stores. It is characterized by inadequate blood levels of the vitamin D, known as 25-hydroxyvitamin D. An estimated 70-90% of CKD patients have vitamin D insufficiency, which can lead to SHPT and resultant debilitating bone diseases. Vitamin D insufficiency has also been associated with increased mortality in CKD. (more…)
Author Interviews, Endocrinology, Health Care Systems, JCEM / 09.07.2014

Robert A. Vigersky, MD Walter Reed National Military Medical Center Bethesda, MDMedicalResearch.com Interview with: Robert A. Vigersky, MD Walter Reed National Military Medical Center Bethesda, MD Medical Research: What type of patients do endocrinologists typically treat and why is the demand for their services anticipated to grow? Dr. Vigersky: Endocrinologists are physicians trained in managing, diagnosing, and treating disorders of the endocrine system:  thyroid, parathyroid, adrenal glands, hypophyseal and hypothalamic axes, ovaries, testes, and pancreas.  Their role involves controlling diabetes mellitus, menopause, hyperthyroidism and other conditions involving metabolism. A major factor affecting the anticipated demand for health care services is the aging population.  In 2010, there were 37.5 million people age 65 or over, constituting about 12.7 percent of the total population, and by 2025 the population age 65 or over will number 62.5 million (17.9 percent of the population).  Due to the greater prevalence of many of the diseases in older age groups, like osteoporosis, diabetes, obesity, and thyroid nodules, the growth in the population age 65 or over will exert a major influence on the demand for endocrine services. Diabetes, by itself, is a major driver of demand.  The incidence of Type 2 diabetes rises dramatically with age, and with obesity.  In an increasingly overweight population an estimated 22.3 million people in the U.S. are diagnosed with diabetes as of 2012, representing about 7 percent of the population. This estimate is higher than but consistent with those published by the CDC for 2010.  The percentage of the population with diagnosed diabetes continues to rise, with one study projecting that as many as one in three U.S. adults could have diabetes by 2050 if current trends continue. (more…)
Author Interviews, BMJ, Endocrinology, Weight Research / 27.06.2014

MedicalResearch.com Interview with: Mojca Jensterle Department of Endocrinology. Diabetes and Metabolic Diseases. University Medical Centre. Zaloska 7. Slovenia. MedicalResearch: What are the main findings of the study? Answer: This is the first report demonstrating that selective phosphodiesterase enzyme (PDE) 4 inhibitor roflumilast added to metformin (MET) was superior to metformin alone in reducing mean body weight after 12 weeks of treatment in obese women with polycystic ovary syndrome (PCOS), primarily due to a loss of fat mass. 31 women with PCOS diagnosed by the National Institute of Child Health and Human Development criteria aged 33.8 ± 7.4 years with BMI 36.4 ± 5.1 kg/m2concluded the study. They were randomized to MET 1000 mg BID or combined treatment (COM) with MET 1000 mg BID and roflumilast 500 mcg QD. The primary outcome were changes in anthropometric measures of obesity. At study endpoint subjects treated with COM lost on average 4.2 ± 2.8 kg compared to a 0.9± 2.5 kg weight gain in METgroup (p<0.001). BMI decreased for 1.6 ± 1.1 kg/m2 in COM arm compared to increase for 0.9 ± 2.4 kg/m2 in MET arm (p= 0.001). Total body fat decreased for 0.7±0.4 % in COM as opposed to 0.2 ± 0.1 % increase in MET and visceral adipose tissue (VAT) area as assessed by DXA decreased for 15.5 ± 1.6 cm2 in COM as opposed to 11.4 ± 5.3 cm2 increase in MET. The greater waist circumference reduction was noted in COM (4.2 ± 1 cm) compared with MET (0.8 ± 0.7 cm). The improvements of obesity measures were associated with beneficial effects on fasting glucose levels, insulin resistance and resolution of metabolic syndrome in affected women. The hypothesis behind the weight decrease and beneficial metabolic impact observed with roflumilast is based on the PDE4 regulation of signaling pathways linked to GLP-1 release. In experimental rodent model a single treatment with roflumilast enhanced plasma GLP-1 levels up to 2.5 -fold. (more…)
Diabetes, Endocrinology, OBGYNE / 26.06.2014

MedicalResearch.com Interview with: Dr Anju Joham PhD student, SPHPM Endocrinologist, Monash Health MedicalResearch: What is the background for your study? Dr. Joham: This research led by Professor Helena Teede and Dr Anju Joham, from the School of Public Health and Preventive Medicine at Monash University analysed a large-scale epidemiological study, called the Australian Longitudinal Study of Women’s Health (ALSWH). Polycystic Ovary Syndrome (PCOS) is a condition affecting nearly 20% of Australian women. Women with PCOS may experience irregular menstrual cycles, reduced fertility, increased risk of diabetes, high cholesterol and psychological features such as depression and reduced quality of life. MedicalResearch: What are the main findings of the study? Dr. Joham:   Approximately 6000 women aged between 25-30 years were monitored for nine years, including nearly 500 women with diagnosed PCOS. Our research found that there is a clear link between PCOS and type 2 diabetes. The incidence and prevalence of type 2 diabetes was three to five times higher in women with PCOS. In analysing the key contributing factors to the increased diabetes risk, we found that having PCOS was in itself a key contributing factor. (more…)
Author Interviews, Endocrinology, JCEM / 20.06.2014

Mette Andersen Nexø Psychologist, Ph.D. student at The National Research Center for the Working Environment Copenhagen Area, DenmarkMedicalResearch.com: Interview with Mette Andersen Nexø Psychologist, Ph.D. student at The National Research Center for the Working Environment Copenhagen Area, Denmark MedicalResearch: What is the background for this study? Answer: The present study is a systematic assessment of the influence of a spectrum of thyroid diseases on ability to work. By presenting new information on the possible socioeconomic consequences of thyroid diseases, the results can help bring awareness to important needs for rehabilitation of thyroid patients. (more…)
Author Interviews, Endocrinology, OBGYNE / 17.06.2014

Sergio R. Ojeda, D.V.M. Division Head and Senior Scientist Division of Neuroscience Division of Neuroscience, OR National Primate Research Center/Oregon Health and Science University, Beaverton OR 97006MedicalResearch.com Interview with: Sergio R. Ojeda, D.V.M. Division Head and Senior Scientist Division of Neuroscience Division of Neuroscience, OR National Primate Research Center/Oregon Health and Science University, Beaverton OR 97006 MedicalResearch: What are the main findings of the study? Dr. Ojeda: The study shows that a receptor for two growth factors (brain-derived neurotrophic factor [BDNF] and neurotrophin 4/5  [NT4/5]) that are known to be important for development of the nervous system is also essential for maintaining oocyte integrity and survival in the mammalian ovary. Intriguingly, the full-length form of this receptor (known as NTRK2-FL) is not expressed in oocytes until the time of the first ovulation. At this time,  the pre-ovulatory gonadotropin discharge stimulates granulosa cells of ovarian follicles to produce not only more BDNF, but also more of a peptide known as kisspeptin, to induce the formation of NTRK2-FL in oocytes. To date, kisspeptin was known to be  only critical for the hypothalamic control of reproduction. To induce NTRK2-FL, BDNF binds to truncated NTRK2 receptors (NTRK2-T1), which are abundant in oocytes throughout prepubertal development.  Kisspeptin, on the other hand, does so by activating its receptor KISS1R, also expressed in oocytes. Once present after the first ovulation, NTRK2-FL is able to activate a survival pathway in oocytes following gonadotropin stimulation, presumably at every cycle. In the absence of NTRK2-FL, oocytes die, follicular structure disintegrates and a condition of premature ovarian failure ensues. (more…)
Author Interviews, Diabetes Care, Endocrinology, Weight Research / 12.06.2014

Christian Benedict PhD Department of Neuroscience Uppsala University Uppsala, SwedenMedicalResearch.com Interview with: Christian Benedict PhD Department of Neuroscience Uppsala University Uppsala, Sweden MedicalResearch: What are the main findings of the study? Dr. Benedict: By utilizing blood samples collected after an overnight fast, we demonstrated that humans carrying a common risk variant of the fat mass and obesity gene (obesity-associated gene (FTO)) (~16% of the population have two copies of this risk variant) had higher fasting blood concentrations of the hunger hormone ghrelin.  In contrast, fasting serum levels of the satiety enhancing hormone leptin were lower. (more…)
Author Interviews, Endocrinology, JCEM / 31.05.2014

Prof. Stefano Palomba Department of Obstetrics and Gynecology University “Magna Graecia” of Catanzaro Catanzaro, ItalyMedicalResearch.com Interview with: Prof. Stefano Palomba Department of Obstetrics and Gynecology University “Magna Graecia” of Catanzaro Catanzaro, Italy MedicalResearch: What are the main findings of the study? Prof. Palomba: Our study demonstrates that simple markers of inflammation, commonly detectable in clinical practice with commercial kits, are significantly modified in women with PCOS during pregnancy and associated at an increased risk of complications during pregnancy in the same population with PCOS. (more…)
Author Interviews, Endocrinology, Genetic Research, Metabolic Syndrome, Weight Research, Yale / 14.05.2014

MedicalResearch Interview with: Arya Mani, M.D. Department of Internal Medicine and Genetics Yale Cardiovascular Research Center Yale, New Haven CT Arya Mani, M.D. Department of Internal Medicine and Genetics Yale Cardiovascular Research Center Yale, New Haven CT MedicalResearch: What are the main findings of the study? Dr. Mani: Our group has identified a gene that when mutated it causes a form of truncal (central) obesity that is associated with a cluster of coronary artery disease risk factors, including high blood pressure, insulin resistance and possibly elevated blood lipids. These associated risk factors are collectively known as the metabolic syndrome, which may lead to development of diseases such as diabetes and coronary artery disease, both of which were very prevalent in the populations we studied. All identified mutations by our group have been so far gain of function mutations, which means they increased the activity of the gene in pathways related to adipogenesis and gluconeogenesis. (more…)
Author Interviews, Endocrinology, Weight Research / 12.05.2014

MedicalResearch Interview with: Alicia J. Kowaltowski, MD, PhD Professor of Biochemistry Departamento de Bioquímica, IQ, Universidade de São Paulo São Paulo, SP, Brazil MedicalResearch: What are the main findings of the study? Dr. Kowaltowski: Intermittent fasting (24 hour cycles of all-you-can-eat followed by 24 fasting) is often used as a way to control excessive weight gain in laboratory animals, despite the fact that these animals overeat on the days they get food, and end up ingesting total quantities of food very similar to animals that eat every day. We show here that although lower weight gain occurs with intermittent fasting and there are some health benefits in adopting this diet, there are also some undesirable consequences. One such consequence is that this diet changes the control of hunger in the hypothalamus within the brain, making the rats hungry all the time, even when they are eating. (more…)
Author Interviews, Endocrinology, JCEM / 28.04.2014

Dr. Dorte Glintborg PhD Senior Hospital Physician, PhD Dorte Glintborg, Department of Endocrinology, OUH Odense University HospitalMedicalResearch.com Interview with: Dr. Dorte Glintborg PhD Senior Hospital Physician, PhD Dorte Glintborg, Department of Endocrinology, OUH Odense University Hospital MedicalResearch.com: What are the main findings of this study? Dr. Glintborg: The main finding of the study is that one year’s metformin treatment is associated with a minor but significant weight loss in patients with PCOS irrespective of BMI at study inclusion. Treatment with oral contraceptives improves sex-hormone levels but is associated with at minor weight gain. Based on the study results, clinicians should consider the combined treatment with metformin and oral contraceptives in patients with PCOS. (more…)
Author Interviews, Endocrinology, Race/Ethnic Diversity, Thyroid Disease / 18.04.2014

MedicalResearch.com Interview with: Donald S. A. McLeod, FRACP, MPH Department of Population Health, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia MedicalResearch.com: What are the main findings of the study? Dr. McLeod: We examined the incidence of Graves’ disease and Hashimoto’s thyroiditis by race/ethnicity among U.S. active duty service personnel aged 20-54 years over a 15-year period (more than 20,000,000 person years follow-up). Cases were identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes. In women, we found that Graves’ disease was almost twice as common among non-Hispanic black and Asian-Pacific Islander personnel compared with non-Hispanic white personnel.  While in men, non-Hispanic black and Asian-Pacific Islander personnel had over two-and-a-half times higher incidence compared with non-Hispanic white personnel. The opposite pattern existed for Hashimoto’s thyroiditis, with non-Hispanic white personnel having the highest incidence, and non-Hispanic black and Asian-Pacific Islander personnel the lowest incidence. Hispanic personnel did not have significantly different incidence compared to white personnel for either disorder. (more…)
Author Interviews, Endocrinology, JCEM / 16.04.2014

Kai-Jen Tien, MD Division of Endocrinology and Metabolism, Department of Internal Medicine, Chi Mei Medical Center Assistant Professor, Center of General Education Chia Nan University of Pharmacy and Science Tainan, TaiwanMedicalResearch.com Interview with: Kai-Jen Tien, MD Division of Endocrinology and Metabolism, Department of Internal Medicine,  Chi Mei Medical Center Assistant Professor, Center of General Education Chia Nan University of Pharmacy and Science Tainan, Taiwan MedicalResearch.com: What are the main findings of the study? Answer:  We conducted the first and largest population-based cohort study to evaluate the association of obstructive sleep apnea (OSA) and osteoporosis in a 6-year follow-up investigation of an Asian population. OSA is characterized by repetitive episodes of apnea/hypopnea and hypoxia in tissue, which might impact the bone metabolism. The results of the study showed that patients with obstructive sleep apnea had 2.74 times the risk of osteoporosis than patents without obstructive sleep apnea after adjustment for the patient`s characteristics and comorbidities. Across all age groups and sex groups, individuals with OSA had higher incidence rate of osteoporosis than individuals without obstructive sleep apnea. Subgroup analysis showed that older patients and female patients had a higher risk for osteoporosis than their younger and male counterparts. (more…)
Author Interviews, Endocrinology, Gastrointestinal Disease, JAMA, Johns Hopkins, Surgical Research / 24.03.2014

Elizabeth C. Wick, MD Assistant Professor,Department of Surgery The Johns Hopkins Hospital, Baltimore, MarylandMedicalResearch.com Interview with: Elizabeth C. Wick, MD Assistant Professor,Department of Surgery The Johns Hopkins Hospital, Baltimore, Maryland   MedicalResearch.com: What are the main findings of the study? Dr. Wick: The main finding is the high variability in physician practice for prescribing steroids and the lack of clear guidance as to best practice in the literature. (more…)
Accidents & Violence, Author Interviews, Endocrinology, Pediatrics, Weight Research / 23.03.2014

MedicalResearch.com Interview with: Christos S. Mantzoros, MD, DSc, PhD Beth Israel Deaconess Medical Center and the VA Boston HealthcareChristos S. Mantzoros, MD, DSc, PhD Beth Israel Deaconess Medical Center and the VA Boston Healthcare Cynthia R. Davis PhD Judge Baker Children’s Center in Boston, MA.Cynthia R. Davis PhD Judge Baker Children’s Center in Boston, MA.     MedicalResearch.com: What are the main findings of this study? Answer: These results highlight that chronic stressors in childhood, like child abuse and family violence, parental substance abuse, divorce and separation from a parental figure, can potentially have a long standing impact on brain structures and functioning, such as the hypothalamic-pituitary-adrenal axis.  Our work supports the notion of allostatic load, and is the first of its kind to demonstrate links between childhood adversity and central obesity later in life which leads to increased cardio metabolic risk. This study describes the role of these novel molecules in mediating metabolic dysregulation highlighting them as a novel mechanism linking childhood adversity to obesity. We have also used more sensitive assessments of childhood adversity, not typically employed in biomedical research, that incorporate the severity of adversities and their chronicity across childhood.  Assessments of this nature are better able to detect severe and chronic adversity, and are critical in the measurement of stress, its role in allostatic load and its impact on the brain.  Furthermore, the current study and others from our lab show that severe and chronic adversity in childhood is associated with metabolic dysregulation and obesity in adulthood, regardless of lifestyle factors such as diet and exercise and psychosocial factors like depression and social support. Clinicians and patients need to be aware of the fact that subjects exposed to early life adversity are at increase risk for central obesity and cardio metabolic risk. (more…)
Author Interviews, Cancer, Endocrinology, Pediatrics, Thyroid / 20.03.2014

Melanie Goldfarb MD Assistant Professor of Surgery, Endocrine Surgery University of Southern California Keck School of Medicine, Los Angeles, CaliforniaMedicalResearch.com Interview with Melanie Goldfarb MD Assistant Professor of Surgery, Endocrine Surgery University of Southern California Keck School of Medicine, Los Angeles, California MedicalResearch.com: What are the main findings of the study? Dr. Goldfarb: Adolescents and young adults (AYAs) who develop thyroid cancer as a secondary cancer are six times more likely to die than AYAs with primary thyroid cancer, though survival with treatment is excellent for both primary and secondary cancers at greater than 95 percent. Additionally, Hispanics, Males, and those of lower socioeconomic status have worse overall survival. (more…)
Author Interviews, BMJ, Endocrinology, General Medicine / 14.02.2014

Simon D. Brandt, PhD Reader in Bioactive Drug Chemistry School of Pharmacy & Biomolecular Sciences Liverpool John Moores University Liverpool, L3 3AF, UK Associate Editor "Drug Testing and Analysis" (Wiley)MedicalResearch.com Interview with: Simon D. Brandt, PhD Reader in Bioactive Drug Chemistry School of Pharmacy & Biomolecular Sciences Liverpool John Moores University Associate Editor "Drug Testing and Analysis" (Wiley) Author's background comment: This type of work represents one of our areas of activity related to multi-disciplinary approaches to harm reduction which combines public health work with research on various properties of bioactive substances. MedicalResearch.com: What are the main findings of the study? Answer: As part of our work related to so-called lifestyle and image-enhancing drugs and legal highs/bath salts, we became interested in a particular "food/dietary supplement" called "Esto Suppress" because it was discussed on some Internet forums dedicated to the topic of bodybuilding. Some forum members were speculating that tamoxifen might be present in this particular product. The reason for this speculation came from the chemical name that was written on the label which pointed in that direction. This particular product was also widely available from a number of online retailers and while some indications existed that the same chemical name was mentioned, others were seen to list a modified version of that name which did not always make much chemical sense. We test purchased four "Esto Suppress" samples in a local fitness store and confirmed that three of them contained the breast cancer drug tamoxifen. (more…)
Author Interviews, Endocrinology, Testosterone / 10.01.2014

J. Bradley Layton, PhD Postdoctoral Research Associate University of North Carolina at Chapel HillMedicalResearch.com Interview with: J. Bradley Layton, PhD Postdoctoral Research Associate University of North Carolina at Chapel Hill MedicalResearch.com: What are the main findings of the study? Dr. Layton: Use of testosterone testing and treatment had greatly increased over the past decade, with more pronounced increases seen in the United States than in the United Kingdom. The increases in testing in the UK seem to be targeted, identifying more men with reduced testosterone levels, but the increases in the US seem to be identifying more and more men with normal levels. Many of the men who begin testosterone treatment in the US appear to have normal testosterone levels to begin with. (more…)
Author Interviews, Endocrinology / 18.12.2013

MedicalResearch.com Interview with: Christopher D Kassotis  (MU-Student) Department of Obstetrics, Gynecology and Women’s Health and Division of Biological Sciences University of Missouri, Columbia, MO 65211; MedicalResearch.com: What are the main findings of the study? Answer: The main findings of our study are twofold: First, we found that 12 chemicals used in the fracking process disrupt hormone action. Specifically, we found that they inhibited the action of estrogens such as estradiol and androgens such as testosterone; classes of reproductive hormones that are critical for normal development and reproductive maturation. Second, we found that surface and ground water from a drilling-dense area in Colorado has much greater hormonal activity than samples from areas with limited drilling. Specifically, ground water had elevated estrogenic activity (mimicking the effects of estrogens), while surface water exhibited anti-estrogenic and anti-androgenic activities, similar to the chemicals we tested. (more…)
Author Interviews, Endocrinology, Menopause, PNAS, Stanford / 28.11.2013

Dr. Victor W. Henderson MD Professor of Health Research and Policy and of Neurology and Neurological Sciences Stanford University, Stanford, CA 94305MedicalResearch.com Interview with: Dr. Victor W. Henderson MD Professor of Health Research and Policy and of Neurology and Neurological Sciences Stanford University, Stanford, CA 94305 MedicalResearch.com: What are the main findings of the study? Dr. Henderson: Estrogen or hormone therapy effects on some health outcomes differ by age, harmful at one age and beneficial at another. This difference is sometimes referred to as the “critical window” or “timing” theory. It is controversial whether the so-called critical-window applies to memory or other cognitive skills. In assessing the critical window hypothesis, we found that the relation between blood levels of estrogen and memory or reasoning skills is the same in younger postmenopausal women as in older postmenopausal women.  Essentially, there is no association at either age. (more…)
Author Interviews, Endocrinology, JCEM, Testosterone / 23.11.2013

Dr Bu Beng Yeap MBBS, FRACP, PhD Professor, School of Medicine and Pharmacology, University of Western Australia Endocrinologist, Department of Endocrinology and Diabetes, Fremantle Hospital. School of Medicine and Pharmacology
Level 2, T Block, Fremantle Hospital, Alma Street, Fremantle, Western Australia 6160, AustraliaMedicalResearch.com Interview with: Dr Bu Beng Yeap   MBBS, FRACP, PhD Professor, School of Medicine and Pharmacology, University of Western Australia Endocrinologist, Department of Endocrinology and Diabetes, Fremantle Hospital. MedicalResearch.com: What are the main findings of the study? Answer: We found that older men with testosterone levels in the middle of the range had the lowest mortality risk. Having a low testosterone level predicted higher mortality, and there was no benefit of having a high-normal testosterone level. Men with optimal rather than high testosterone levels lived longest. The other important finding was that men with higher dihydrotestosterone levels had lower mortality from ischaemic heart disease, suggesting that androgens may protect against heart disease in older men. (more…)
Author Interviews, Endocrinology / 14.10.2013

MedicalResearch.com Interview with: Dr. Liora Lazar The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes National Center for Childhood Diabetes Schneider Children's Medical Center of Israel 14 Kaplan St., Petah Tikva 49202, Israel MedicalResearch.com: What are the main findings of the study? Dr. Lazar: The study aims to assess the reproductive outcome and social adjustment of former Central precocious puberty (CPP) women between the 3rd and 5th decades of life. The main findings of this study are: 1.       Clinical hyperandrogenism was more prevalent among former CPP women, both treated and untreated, as compared to controls. 2.      Fertility problems were more prevalent only among untreated–CPP women. 3.       Educational achievements and marital status were similar in former CPP women and their controls. (more…)
Author Interviews, Endocrinology, Thyroid Disease / 31.05.2013

Pauline Mendola, PhD Investigator Epidemiology Branch Division of Epidemiology, Statistics and Prevention Research Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH Rockville, MD 20852MedicalResearch.com eInterview with Pauline Mendola, PhD Investigator Epidemiology Branch Division of Epidemiology, Statistics and Prevention Research Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH Rockville, MD 20852 MedicalResearch.com: What are the main findings of the study? Dr. Mendola: Women with thyroid disease during pregnancy had more obstetric complications including preeclampsia and preterm birth.  They were also more likely to be admitted to an intensive care unit during their delivery admission. (more…)